| [1] |
Xu Q, Du W, Zhou H, et al. Distinct clinical characteristics of paraneoplastic optic neuropathy [J]. Br J Ophthalmol, 2019, 103(6): 797-801.
|
| [2] |
Bataller L, Dalmau J. Neuro-ophthalmology and paraneoplastic syndromes [J]. Current Opinion in Neurology, 2004, 17(1): 3-8.
|
| [3] |
Adamus G. Autoantibody targets and their cancer relationship in the pathogenicity of paraneoplastic retinopathy [J]. Autoimmun Rev, 2009, 8(5): 410-414.
|
| [4] |
Adamus G. Are Anti-Retinal Autoantibodies a Cause or a Consequence of Retinal Degeneration in Autoimmune Retinopathies? [J]. Front Immunol, 2018, 9(765): 1-4.
|
| [5] |
Hoogewoud F, Butori P, Blanche P, et al. Cancer-associated retinopathy preceding the diagnosis of cancer [J]. BMC Ophthalmol, 2018, 18(1): 285-290.
|
| [6] |
Rahimy E, Sarraf D. Paraneoplastic and non-paraneoplastic retinopathy and optic neuropathy: evaluation and management [J]. Surv Ophthalmol, 2013, 58(5): 430-458.
|
| [7] |
Gordon LK. Paraneoplastic Syndromes in Neuro-Ophthalmology [J]. Journal of Neuro-Ophthalmology, 2015, 35(3): 306-314.
|
| [8] |
Bussat A, Langner-Lemercier S, Salmon A, et al. Paraneoplastic syndromes in ophthalmology [J]. Journal Franais Dophtalmologie, 2018, 41(5): e181-e185.
|
| [9] |
Roels D, Ueno S, Talianu CD, et al. Unilateral cancer-associated retinopathy: diagnosis, serology and treatment [J]. Doc Ophthalmol, 2017, 135(3): 233-240.
|
| [10] |
Ohguro H, Yokoi Y, Ohguro I, et al. Clinical and Immunologic Aspects of Cancer-associated Retinopathy [J]. Am J Ophthalmol, 2004, 137(6): 1117-1119.
|
| [11] |
Parc CE, Azan E, Bonnel S, et al. Cone Dysfunction as a Paraneoplastic Syndrome Associated with Retinal Antigens Approximating 40 kiloDalton [J]. Ophthalmic Genet, 2006, 27(2): 57-61.
|
| [12] |
Mohamed Q, Harper CA. Acute Optical Coherence Tomographic Findings in Cancer-Associated Retinopathy [J]. Arch Ophthalmol, 2007, 125(8): 1132-1133.
|
| [13] |
Lima LH, Greenberg JP, Greenstein VC, et al. Hyperautofluorescent ring in autoimmune retinopathy [J]. Retina, 2012, 32(7): 1385-1394.
|
| [14] |
Shildkrot Y, Sobrin L, Gragoudas ES. Cancer-associated retinopathy: update on pathogenesis and therapy [J]. Semin Ophthalmol, 2011, 26(4-5): 321-328.
|
| [15] |
Dalin F, Adamus G, Yang S, et al. Aryl Hydrocarbon Receptor-Interacting Protein-Like 1 in Cancer-Associated Retinopathy [J]. Ophthalmology, 2016, 123(6): 1401-1404.
|
| [16] |
Thirkill CE, Roth AM, Keltner JL. Cancer-associated retinopathy [M]. Springer Berlin Heidelberg, 1987, 105(3): 372-375.
|
| [17] |
Polans AS, Witkowska D, Haley TL, et al. Recoverin, a photoreceptor-specific calcium-binding protein, is expressed by the tumor of a patient with cancer-associated retinopathy [J]. Proc Natl Acad Sci U S A, 1995, 92(20): 9176-9180.
|
| [18] |
Adamus G, Ren G, Weleber RG. Autoantibodies against retinal proteins in paraneoplastic and autoimmune retinopathy [J]. BMC Ophthalmol, 2004, 4(1): 5-14.
|
| [19] |
Adamus G, Brown L, Weleber RG. Molecular biomarkers for autoimmune retinopathies: significance of anti-transducin-alpha autoantibodies [J]. Experimental and molecular pathology, 2009, 87(3): 195-203.
|
| [20] |
Ohguro H, Ogawa KI, Maeda T, et al. Cancer-associated retinopathy induced by both anti-recoverin and anti-hsc70 antibodies in vivo [J]. Invest Ophthalmol Vis Sci, 1999, 40(13): 3160-3167.
|
| [21] |
Adamus G, Karren L. Autoimmunity against carbonic anhydrase II affects retinal cell functions in autoimmune retinopathy [J]. Journal of Autoimmunity, 2009, 32(2): 133-139.
|
| [22] |
Adamus G. Autoantibody-induced apoptosis as a possible mechanism of autoimmune retinopathy [J]. Autoimmunity Reviews, 2003, 2(2): 63-68.
|
| [23] |
Evoy F, Lafortune J. First case of melanoma-associated retinopathy with conjunctival melanoma [J]. Canadian Journal of Ophthalmology, 2020, 55(4): e153-e155.
|
| [24] |
Yagyu K, Ueda T, Miyamoto A, et al. Cancer-associated Retinopathy with Neuroendocrine Combined Large-cell Lung Carcinoma and Adenocarcinoma [J]. Intern Med, 2019, 58(22): 3289-3294.
|
| [25] |
Khan N, Huang JJ, Foster CS. Cancer Associated Retinopathy (CAR): An Autoimmune-Mediated Paraneoplastic Syndrome [J]. Seminars in Ophthalmology, 2006, 21(3): 135-141.
|
| [26] |
Ramos-Ruperto L, Busca-Arenzana C, Boto-De Los Bueis A, et al. Cancer-Associated Retinopathy and Treatment with Intravenous Immunoglobulin Therapy. A Seldom Used Approach? [J]. Ocular immunology and inflammation, 2019: 1-4.
|
| [27] |
Keltner JL, Thirkill CE, Yip PT. Clinical and immunologic characteristics of melanoma-associated retinopathy syndrome: eleven new cases and a review of 51 previously published cases [J]. Neuroophthalmol, 2001, 21(3): 173-187.
|
| [28] |
Elsheikh S, Gurney SP, Burdon MA. Melanoma-associated retinopathy [J]. Clinical and Experimental Dermatology, 2019, 45(2): 147-152.
|
| [29] |
Duvoisin RM, Haley TL, Ren G, et al. Autoantibodies in Melanoma-Associated Retinopathy Recognize an Epitope Conserved Between TRPM1 and TRPM3 [J]. Investigative Ophthalmology and Visual Science, 2017, 58(5): 2732-2738.
|
| [30] |
Janaky M, Palffy A, Kolozsvari L, et al. Unilateral manifestation of melanoma-associated retinopathy [J]. Arch Ophthalmol, 2002, 120(6): 866-867.
|
| [31] |
Powell SF, Dudek AZ. Treatment of Melanoma-Associated Retinopathy [J]. Current Treatment Options in Neurology, 2010, 12(1): 54-63.
|
| [32] |
Machida S, Ohguro H, Tateda M, et al. Melanoma-associated retinopathy associated with intranasal melanoma [J]. Documenta Ophthalmologica, 2011, 122(3): 191-197.
|
| [33] |
Audemard DA, Raucourt SD, Miocque S, et al. Melanoma-associated retinopathy treated with ipilimumab therapy [J]. Dermatology, 2013, 227(2): 146-149.
|
| [34] |
Alexander KR, Fishman GA, Peachey NS, et al. 'On' response defect in paraneoplastic night blindness with cutaneous malignant melanoma [J]. Investigative Ophthalmology and Visual Science, 1992, 33(3): 477-483.
|
| [35] |
Koike C, Obara T, Uriu Y, et al. TRPM1 is a component of the retinal ON bipolar cell transduction channel in the mGluR6 cascade [J]. Proceedings of the National Academy of Sciences, 2009, 107(1): 332-337.
|
| [36] |
Powell SF, Dudek AZ. Treatment of Melanoma-Associated Retinopathy[J]. Current Treatment Options in Neurology, 2010, 12(1): 54-63.
|
| [37] |
Pfohler C, Preuss KD, Tilgen W, et al. Mitofilin and titin as target antigens in melanoma-associated retinopathy [J]. International Journal of Cancer, 2007, 120(4): 788-795.
|
| [38] |
Yamamoto S, Hanaya J, Mera K, et al. Erratum to: Recovery of visual function in patient with melanoma-associated retinopathy treated with surgical resection and interferon-beta [J]. Documenta Ophthalmologica, 2012, 124(2): 143-147.
|
| [39] |
Verdaguer J, Oporto J. Bilateral diffuse uveal melanocytic proliferation associated with renal cell carcinoma [J]. Retin Cases Brief Rep, 2013, 7(2): 137-139.
|
| [40] |
Barr CC. Bilateral diffuse melanocytic uveal tumors associated with systemic malignant neoplasms. A recently recognized syndrome [J]. Arch Ophthalmol, 1982, 100(2): 249-255.
|
| [41] |
Klemp K, Kiilgaard JF, Heegaard S, et al. Bilateral diffuse uveal melanocytic proliferation: Case report and literature review [J]. Acta Ophthalmol, 2017, 95(5): 439-445.
|
| [42] |
Oneal KD, Butnor KJ, Perkinson KR, et al. Bilateral diffuse uveal melanocytic proliferation associated with pancreatic carcinoma: a case report and literature review of this paraneoplastic syndrome [J]. Survey of Ophthalmology, 2003, 48(6): 613-625.
|
| [43] |
Gass J. Bilateral diffuse uveal melanocytic proliferation in patients with occult carcinoma [J]. Archives of ophthalmology, 1990, 108：527-533.
|
| [44] |
Lee JM, Seong HK, Nam WH, et al. Cancer-associated Nummular Loss of the Retinal Pigment Epithelium [J]. Korean Journal of Ophthalmology Kjo, 2007, 21(4): 261-264.
|
| [45] |
Tanaka M, Kamoi K, Nagaoka N, et al. Bilateral diffuse retinal pigment epithelium proliferation induced by choroidal inflammation: A case report [J]. Medicine (Baltimore), 2019, 98(47): e18152.
|
| [46] |
Navajas EV, Simpson ER, Krema H, et al. Cancer-associated nummular loss of RPE: expanding the clinical spectrum of bilateral diffuse uveal melanocytic proliferation [J]. Eye, 2011, 42: e103-106.
|
| [47] |
Golshahi A, Bornfeld N, Weinitz S, et al. Near-infrared autofluorescence in bilateral diffuse uveal melanocytic proliferation associated with esophageal carcinoma and choroidal metastasis[J]. Retinal Cases and Brief Reports, 2016, 10(3): 254-258.
|
| [48] |
Shiraki A, Winegarner A, Hashida N, et al. Diagnostic evaluation of optical coherence tomography angiography and fundus autofluorescence in bilateral diffuse uveal melanocytic proliferation [J]. Am J Ophthalmol, 2018, 11：32-34.
|
| [49] |
Chahud F, Young RH, Remulla JF, et al. Bilateral diffuse uveal melanocytic proliferation associated with extraocular cancers: review of a process particularly associated with gynecologic cancers [J]. Am J Surg Pathol, 2001, 25(2): 212-218.
|
| [50] |
Miles SL, Niles RM, Pittock S, et al. A factor found in the IgG fraction of serum of patients with paraneoplastic bilateral diffuse uveal melanocytic proliferation causes proliferation of cultured human melanocytes [J]. Retina, 2012, 32(9): 1959-1966.
|
| [51] |
Jansen JCG, Van Calster J, Pulido JS, et al. Early diagnosis and successful treatment of paraneoplastic melanocytic proliferation [J]. Br J Ophthalmol, 2015, 99(7): 943-948.
|
| [52] |
Hoh AE, Holz FG, Dithmar S. Bilateral diffuse uveal melanocytic proliferation in a patient with metastatic breast cancer [J]. Der Ophthalmologe, 2014, 111(10): 961-964.
|
| [53] |
Jansen J, Van Calster J, Pulido JS, et al. Early diagnosis and successful treatment of paraneoplastic melanocytic proliferation [J]. Br J Ophthalmol, 2015, 99(7): 943-948.
|
| [54] |
Jaben EA, Pulido JS, Pittock S, et al. The potential role of plasma exchange as a treatment for bilateral diffuse uveal melanocytic proliferation: a report of two cases [J]. J Clin Apher, 2011, 26(6): 356-361.
|